A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation

[1]  D. Linch,et al.  Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures , 1997, Bone Marrow Transplantation.

[2]  J. Vose,et al.  Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow , 1997, Bone Marrow Transplantation.

[3]  L. Kanz,et al.  Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. , 1996, Bone marrow transplantation.

[4]  E. Shpall,et al.  Mobilization and selection of CD34-positive hematopoietic progenitors. , 1996, Blood reviews.

[5]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[6]  J. Rossi,et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.

[7]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[8]  S. Langabeer,et al.  Accessory cells do not contribute to G‐CSF or IL‐6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation , 1995, British journal of haematology.

[9]  A. Lichtenstein,et al.  Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. , 1995, Blood.

[10]  D. Huhn,et al.  Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Nienhuis,et al.  Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. , 1995, Blood.

[12]  N. Schmitz,et al.  G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. , 1995, Experimental hematology.

[13]  N. Schmitz,et al.  Allogeneic transplantation of peripheral blood progenitor cells. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Lichtenstein,et al.  The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. , 1994, Blood.

[15]  L. Kanz,et al.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. , 1994, Blood.

[16]  L. To,et al.  Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. , 1993, Bone marrow transplantation.

[17]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[18]  W. Anderson,et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation , 1993, The Lancet.

[19]  I. Bernstein,et al.  Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. , 1991, Blood.

[20]  M. Zutter,et al.  Epstein-Barr virus lymphoproliferation after bone marrow transplantation. , 1988, Blood.

[21]  D. Weisenburger,et al.  Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. , 1988, Blood.

[22]  I. Bernstein,et al.  Antigen CD34+ marrow cells engraft lethally irradiated baboons. , 1988, The Journal of clinical investigation.

[23]  R. Bast,et al.  ANTI-B1 MONOCLONAL ANTIBODY AND COMPLEMENT TREATMENT IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR RELAPSED B-CELL NON-HODGKIN'S LYMPHOMA , 1984, The Lancet.

[24]  M. Fackler,et al.  Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. , 1984, Journal of immunology.

[25]  J. Kemshead,et al.  REMOVAL OF NEUROBLASTOMA CELLS FROM BONE MARROW WITH MONOCLONAL ANTIBODIES CONJUGATED TO MAGNETIC MICROSPHERES , 1984, The Lancet.

[26]  G. Janossy,et al.  T cell regeneration after allogeneic bone marrow transplantation. , 1983, Clinical and experimental immunology.